Greetings, and welcome to the CryoLife fourth quarter and year end 2010 financial conference call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instruction) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Steve Anderson, President and CEO for CryoLife. Thank you Mr. Anderson you may begin.

Good morning everyone. This is Steve Anderson, CryoLife’s CEO, and I would like to welcome you to CryoLife’s year end conference call. With me today is Ashley Lee, the company’s Executive Vice President, COO and CFO. This morning we announced record revenues for CryoLife of $116.6 million and earnings of $0.14 per share. Ashley will discuss the revenues and earnings in more detail in just a few minutes. The fourth quarter of 2010 was a very busy time for CryoLife management. As you will recollect we closed on a manufacturing and distribution agreement with Starch Medical for a powdered hemostat product that they have been marketing in Europe. This assures our participation in a worldwide market estimated to be about $2 billion. This manufacturing and distribution agreement gives us access to all medical specialties in our territory. I will comment more completely on this in a few minutes. The agenda for the conference call today is as follows Ashley will discuss today’s press release in detail and will comment on the growth that we have seen in our business in 2010. I will comment on the manufacturing and distribution agreement with Starch Medical and our international and domestic strategies for launches this product throughout the world. I will also comment on the recent approval of BioGlue in Japan. I will comment on the pending Humane Device Exemption approval of the SynerGraft processed Aortic Valve. And I will comment on the BioFoam European post market study and the BioFoam IDE study that is beginning in the U.S. After my comments have been completed Ashley will return to give you some financial guidance for the rest of 2011. After the guidance comments we will open the call up for questions. At this time Ashley will comment on today’s press release.

Thanks Steve. To comply with the Safe Harbor requirements of the Private Securities Litigation Reform Act of 1995 I would like to make the following statement. Comments made in this call which look forward in time, involve risk and uncertainties and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements include statements made as to the company’s or management’s intentions, hopes, beliefs, expectations or predictions of the future. Including the guidance for 2011 that I will provide in a moment. Additional information concerning risk and uncertainties that may impact these forward-looking statements is contained from time-to-time in the company's SEC filings, including the risk factor section of our previously filed Form 10-K for the year ended December 31, 2009 and our previously filed Form 10-Qs for the quarters ended March 31, June 30 and September 30, 2010, and our Form 10-K for the year ended December 31, 2010 which we expect to file shortly and in the press release that went out this morning. On the call today I will discuss certain non-GAAP financial measures. You can also find the comparable GAAP measures and the reconciliation of these non-GAAP measures to the applicable GAAP measures as scheduled to the press release that went out this morning, a copy of which is contained on the Investor Relations portion of our website. This morning we reported our results for the fourth quarter and full year of 2010 we set all time fourth quarter and full year revenue records of $29.2 million and $116.6 million for the periods ended December 31, 2010. As of December 31, 2010 we had $40.8 million in cash, cash equivalents and restricted securities which includes $1.7 million received from the DOD and $5.3 million in restricted securities. The $40.8…

As I stated earlier in the call the recent license distribution and manufacturing agreement that we signed with Starch Medical for their powdered hemostat PerClot assures CryoLife’s participation in worldwide market estimated to be in excess of $2 billion. The Starch powered hemostat product PerClot appears to be the most effective powdered hemostat in the world. Our scientists estimate that it absorbs two to three times more water than the other powdered hemostat products that are currently available. For the ten weeks last year that we were able to market PerClot internationally we sold $264,000 worth of the product. We shipped about $838,000 in total powdered hemostat sales internationally during the fourth quarter. PerClot is an extremely complementary product to our BioGlue surgical adhesive as it can be used in wet surgical fields and it will biodegrade in about 48 hours. It initiates hemostats immediately when it is confronted by blood from a wound. So far in the early distribution and introduction phase of the marketing of PerClot we have sold it in 17 separate countries throughout the world. We are actively engaged in securing approval of PerClot in additional countries. In preparation for our U.S. FDA Investigational Device Exemption submission animal efficacy studies in the bio compatibility tests are ongoing for PerClot and will be completed in early March of this year. A key opinion leader meeting will be held at CryoLife at first week of March of this year to finalize the investigational plan. We expect to file the company’s IDE at the end of this quarter. Our proposed investigational study is designed to enroll a total of approximately 300 subjects across 10 investigational sites in the clinical trial. It is our expectation that we will begin manufacturing PerClot in our corporate headquarter facilities in late 2011. Management…

We expect total revenues for the full year of 2011 to be between $120 million and $126 million, which includes between $0.5 million and $1 million related to BioFoam funding, received from the DOD. We expect tissue processing revenues to increase between mid single and low double digits on a percentage basis in 2011 compared to 2010. BioGlue and BioFoam revenues to increase by mid single digits on a percentage basis in 2011 compared to 2010. With revenues from powdered hemostats including HemoStase and PerClot to be between $4 million and $6 million. R&D expenses are expected to be between $10 million and $12 million in 2011. We expect earnings per share of between $0.26 and $0.30 in 2011. We expect our effective income tax rate for 2011 to be around 40%. We continue to evaluate opportunities on the business development fronts at it means to accelerate the growth of the company and we continue to invest in our R&D pipeline which reflected in our guidance. Given our strong financial performance and cash position we are well positioned front to identify complementary products or companies that we can acquire to leverage our existing infrastructure and sales force. We continue to believe business development efforts are prudent use of our cash reserves in the strategy that will create value for our shareholder. That concludes my comments and now I will turn it back over to Steve.

Thank you Ashley and now we are going to open up the call for questions.

Thank you. We will now be conducting the question and answer session. (Operator Instructions) Thank you. Our first question today is from the line of Matt Palmer with Roth Capital Partners. Please proceed with you question. Matt Palmer – Roth Capital Partners: Hi good morning Steve and Ashley how are you?

Good morning.

Hey Matt. Matt Palmer – Roth Capital Partners: First question actually on the guidance side just a couple of moving parts first on the revenue can you help us understand how as HemoStase comes out I believe at the end of March how should we expect kind of the revenue progression this year to differ from prior years and then secondly where are you with respect to R&D in terms of PerClot and is that ramping or have we seen a pretty quick level to base up here in Q4.

Okay, I will try to answer your first question regarding PerClot and HemoStase revenues in 2011. To give you a maybe kind of a basis for you know what we are projecting in 2011 if you look at 2010 we generated about $2.4 million in international revenues from powdered hemostats that’s the base of business that we are working off as we go into 2011. Has been documented we will seize to distribute HemoStase in the March of this year. So from the same point of powdered hemostats in general we expect the first quarter to be pretty good we will obviously drop off a little bit in the second quarter because we are going to be distributing fairly in international markets and we expect the ramp you know the revenues to ramp up throughout the remainder of the year as we move forward. So that was on the revenue side on the R&D side in the fourth quarter of 2010 we’ve spent roughly $0.5 million maybe a little bit more than that on PerClot R&D and that was predominantly related to the large animal studies necessary to submit for the IDE which we Steve mentioned earlier we hope to get in at the end of this quarter of very early in the second quarter. Our anticipation is that we will be enrolling patients later this year. So you know there might be a little bit of a low in expenses in the near term but once we begin enrollment we expect it to be ramping and we will be spending you know a significant amount of money and a lot of the increase that we are seeing year over year in R&D expenses is related to PerClot. Matt Palmer – Roth Capital Partners: Okay, great on the business development side it appears to be one of your priorities this year I guess again a two part question the opportunities that you called out in terms of expenses in the fourth quarter are those still ongoing and available to you and then maybe you could just generalize and help us understand what you are looking forward perspective to stage of regulatory or commercial status or anything you might acquire in license.

Okay, as evidenced in our press release and what we said on the call a little bit earlier. We spent significant amount of money in the fourth quarter evaluating more than one opportunity on the business development front and those options remain very viable at this time. So that’s all I will say about you know the opportunities that we are looking at but we are looking at more than one and we are finding some interesting things out there. Your second question was more focused on maybe it would generally we might be looking at an what stage you know our preference is obviously to find things that are related to the markets that we are currently distributing into so cardiac and vascular surgery so those are obviously curious that we’ve remained very focused on we also would preferably like to acquire revenues you know so we are focused on acquiring revenues and if not immediate opportunities where they are very near term pathway revenues. So that’s kind of what we are focusing on. Matt Palmer – Roth Capital Partners: Okay, I will let someone else get on. Thanks guys.

Our next question is from the line of Joe Munda Sidoti and Company. Please state your questions.

Hello Joe. How are you?

Mr. Munda your line is open for your question. Okay. We will move on to Raymond Myers with The Benchmark Company. Please go ahead with your question sir. Raymond Myers – The Benchmark Company: Yeah, thank you I’m here. Ashley and Steve could you maybe start with reminding us how many sales people do you have now and what are your plans to expand that.

In round numbers we have about 50 in the field in United States and we are direct in the UK, Germany and Austria with approximately 10 people in the field over there. Raymond Myers – The Benchmark Company: Great and in the past we’ve, you’ve mentioned a porcine dermis product for Hernia repair that you are expecting to launch early in 2011 where does that stand.

We continue to remain in discussions with some potential partners to try and get that product commercialized if all goes according to plan we could be I’m referring actually to ProPatch right now Ray and with ProPatch we could potentially be first in human implants late this quarter or early in the second quarter. The porcine dermis product that we are working on remains in the R&D shop at this point we are getting very close to a design lock on that particular product and obviously the thought would be to take both of these products ProPatch to build on pure cardio product as well as the porcine dermis product and hopefully work with the same partner for those two products in the general surgery area. Raymond Myers – The Benchmark Company: And would those require flat 10-K.

ProPatch already has a flat 10-K but porcine dermis product would require a flat 10-K. Raymond Myers – The Benchmark Company: Okay. Good. When were you targeting PerClot approval and launch?

I think that PerClot’s approval will be sometime towards the end of 2012 or early 2013 the clinical study that we are going to run is includes about 300 patients and will be across a number of different specialties for a number of different indications. But I would say the soonest we could get it done at the end of 2012 probably a more timely expectation is early 2013. Raymond Myers – The Benchmark Company And that’s for approval or for finishing this study.

That’s approval. Raymond Myers – The Benchmark Company: And so well let’s start with the study through this to finish the 300 patient study if you would follow your IDE at the end of March when do you think you can finish the study.

It will go pretty quickly but I don’t think that we would be finished with the 300 patient enrollment until fourth quarter of 2011. Raymond Myers – The Benchmark Company: And that leaves about a year for FDA is that your thought?

Yeah. Raymond Myers – The Benchmark Company: Great, your HemoStase revenue was quite strong in the fourth quarter is that related to winding down the sales and a desirable push out the last of your inventory before you can’t sell it anymore or does that more represent underlying strength in the market.

I think it represents both you know I mean you know this full area of powdered hemostatic agents is rolling and that’s why we’ve made the commitment to be in it long-term with the acquisition of the PerClot distribution rights and at the same time you know as you mentioned we do have some inventory that we are trying to sell prior to our discontinuing distributing HemoStase which is going to be in late March so it’s a combination of both. Raymond Myers – The Benchmark Company: So should we expect similar sales on Q1 as if we saw in Q4.

For HemoStase. Raymond Myers – The Benchmark Company: Yeah.

No. Raymond Myers – The Benchmark Company: Lower, higher?

That would be lower than the fourth quarter of 2010 and I think that our guidance for again for the full year for all powdered hemostats is between $4 million and $6 million. Raymond Myers – The Benchmark Company Okay, and is some of the HemoStase that you might be selling in Q1 product that is already written off?

Potentially. Raymond Myers – The Benchmark Company: So there could be a potential of a reversal of the prior charges?

I wouldn’t say a reversal of the prior charges we could be recognizing some revenue for which there is no associated – costs associated with the revenues so not by that finish in reversal but we could have some revenue with very high gross margin on it. Raymond Myers – The Benchmark Company: Do you expect that to be potentially meaningful to earnings in the quarter.

I wouldn’t expect it to be meaningful to earnings in the quarter. Raymond Myers – The Benchmark Company: Okay well.

It might be meaningful to cash flow though. Raymond Myers – The Benchmark Company: Nice your cash flow is already very good. You’ve had a share buyback consistently through 2010 do you intend to continue that in 2011?

The buyback has continued into the first couple of months of 2011 and just to give you an idea of where we are we have purchased roughly about 1.3 million to 1.4 million stock in the first two months 2011 at an average price of you know somewhere around 5.25 [ph] that’s a guess. Raymond Myers – The Benchmark Company: So you’ve purchased $1.3 million or shares?

Dollars. Raymond Myers – The Benchmark Company: Dollars.

An average price of somewhere around 5.25 [ph] you know give or take. Raymond Myers – The Benchmark Company: 25 in Q1 great. Good. And what was the fourth quarter capital expense.

Capital expenditures? Raymond Myers – The Benchmark Company: Yeah CapEx.

You know I don’t have that number right at my finger tips Ray you know for the entire year of 2010 it was a little over $2 million and for 2011 you know we would anticipate CapEx to be somewhere between $1.5 million to $2 million. And it’s predominantly maintenance CapEx and then there is some CapEx probably $100,000 to $200,000 to the most associated with setting up the PerClot manufacturing process. Raymond Myers – The Benchmark Company: Okay, excellent.

Great. Raymond Myers – The Benchmark Company: Thank you.

Thank you. Our question is going to be coming from the line of Joseph Munda of Sidoti & Company. Please go ahead with your question sir. Joseph Munda – Sidoti & Company: Good morning guys.

Hello Joseph.

Good morning. Joseph Munda – Sidoti & Company: Died out there from technical difficulties had to switch phones. A lot of the questions I had were already answered but I was wondering if you guys shed a little bit more light on the government agreement with BioFoam and is that something that you guys are aggressively pursuing more government contracts. Tim Lee – Piper Jaffray: Well Department of Defense has been funding that for the last few years and that has to come through an appropriation committee in the house of representatives and we are anticipating that that will continue throughout 2011 I don’t know if it will continue after that. Joseph Munda – Sidoti & Company: Okay and is it was it a open bidding process were you competing with other companies or did the government contact you.

Government contacted us and as far as I know there wasn’t any kind of a bidding contest or anything. Joseph Munda – Sidoti & Company: Okay, thank you and that’s all I had.

Thank you. Our next question is from the line of Tim Lee with Piper Jaffray. Please state your question sir. Tim Lee – Piper Jaffray: Yes good morning and thanks for taking the question. Just in terms of PerClot what’s been kind of the early feedback from customers are you starting to see reorders or are you seeing but definitely seeing customers move away from this.

The early response to the product has been excellent. And when you compare it to other powdered hemostats the chemical reaction of PerClot is visibly striking. It immediately absorbs large quantities of fluid. It forms a very strong a much stronger clot than competitive products. It’s a stickier clot and more effective clot I believe I could say that and generally the physicians are impressed with the chemical reaction of how it works. Next time we see you I will try to remember to put some in my pocket and show you. Tim Lee – Piper Jaffray: Excuse me but given some of those characteristics that you are talking about the fact that you do it is visually more effective and the like are you giving a premium for this relative to HemoStase or you is it being priced comparably or is it being priced.

Priced comparably. Tim Lee – Piper Jaffray: Right okay, okay. And then just kind of certainly back on the earlier question in terms of the HemoStase inventory write off that was taken last quarter in terms of you working through your HemoStase inventory is it kind of in line with what you are thinking or is it reducing quicker than you thought any color you could provide on that front please.

It was pretty much in line with what we were thinking I think as of the end of the year we had about $550,000 of cost to HemoStase inventory still in inventory so you know our goal was obviously to distribute all that and do more but you know as it stands right now it’s pretty much in line with what we had anticipated. Tim Lee – Piper Jaffray: Got it and then just lastly in terms of your cash you are sitting on a good in a good chunk of cash you are generating giving around so that if you have to prioritize your use of cash how would business development rank relative to share buybacks I mean in, on a business development side how big are the assets that you are looking at should we think of a large portion of this cash should be used for business development or should we think of that a large portion would be used for share buyback.

If we had to prioritize I think that business development is first and ahead of share buybacks. You know when we initiated our share buyback last year or were in the past you know we did that recognizing the fact that there were some business development assets out there that we wanted to pursue and we thought that we could do both and that’s what we have been doing and then so going forward we will continue to balance you know the assets that we are pursuing as well and balance that with our ability to continue share buyback but business development is definitely taken the priority at this particular time. As far as I think the size of the assets that we are looking at we are not going to limit ourselves to size I mean obviously we’ve got $41 million in cash as of the end of the year we have credit facilities that are available to us. We have the ability to take on some leverage if we need to you know depending on what opportunity presents itself. So you know we are not going to limit ourselves to an acquisition being too small or too large we are going to pursue things that make sense for our organization going forward and make sure that they did in strategically with you know where Steve wants to take the company and we will leave it at that. Tim Lee – Piper Jaffray: Great, thank you I will jump back in queue.

Ladies and gentlemen we have reached the end of our allotted time for question and answer session today. I will now turn the call back over to management for closing comments.

Thank you very much for joining us today and we look forward to talking with you at the end of the first quarter.

This concludes today’s teleconference. You may disconnect your line at this time. Thank you for your participation.